IMMNOV.ST STO
Immunovia AB
1W: -45.6%
1M: -42.3%
3M: -61.6%
YTD: -59.8%
1Y: -90.7%
3Y: -92.6%
5Y: -99.9%
kr 0.08 ($0.01)
-0.01 (-10.59%)
Weekly Expected Move ±24.2%
kr 0
kr 0
kr 0
kr 0
kr 0
Overview
Chart
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Analysis
Technicals
Weather
Peers
Income Trends
Revenue
$685K
-26.4% ▼
5Y CAGR: +13.6%
Gross Profit
-$80M
-8639.6% ▼
Operating Income
-$80M
+27.3% ▲
Net Income
-$146M
-90.6% ▼
EPS (Diluted)
$-0.42
+54.8% ▲
EBITDA
-$77M
-26.0% ▼
Profit Margins
Year-over-Year Growth
View Full Income Statement
| Line Item | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| Revenue | $844K | $1M | $2M | $931K | $685K |
| YoY Growth | +133.1% | +35.7% | +37.6% | -40.9% | -26.4% |
| Cost of Revenue | -$15M | $4M | $7M | $108M | $80M |
| Gross Profit | $16M | -$3M | -$5M | $931K | -$80M |
| Gross Margin | 1873.6% | -267.8% | -324.3% | 100.0% | -11606.4% |
| R&D Expenses | $43M | $48M | $34M | $28M | $0 |
| SG&A Expenses | $83M | -$48M | $148M | -$28M | $0 |
| Operating Expenses | $183M | $188M | $291M | $110M | $0 |
| Operating Income | -$167M | -$191M | -$296M | -$109M | -$80M |
| Operating Margin | -19756.0% | -16694.3% | -18822.9% | -11752.0% | -11606.4% |
| Interest Expense | $1M | $2M | $1M | $2M | $66M |
| Income Before Tax | -$156M | -$168M | -$309M | -$77M | -$146M |
| Tax Expense | $1M | -$23M | $0 | $0 | $0 |
| Net Income | -$157M | -$145M | -$309M | -$77M | -$146M |
| Net Margin | -18649.1% | -12666.7% | -19646.9% | -8221.4% | -21301.5% |
| EPS (Diluted) | $-6.45 | $-5.95 | $-7.95 | $-0.93 | $-0.42 |
| EBITDA | -$135M | -$142M | -$167M | -$61M | -$77M |
| Shares Outstanding | 24M | 24M | 39M | 83M | 344M |